Zepp Health (ZEPP) EBITDA (2016 - 2026)

Zepp Health has reported EBITDA for 11 years, with the latest figure at -$12.3 million in Q2 2026.

• On a quarterly basis, EBITDA fell 101.72% year-over-year to -$12.3 million in Q2 2026; TTM through Jun 2026 was -$34.8 million, a 24.37% increase from a year earlier, with the FY2025 full-year figure at -$29.2 million, up 38.14% from the prior year.
• EBITDA was -$12.3 million for Q2 2026 at Zepp Health, up from -$17.7 million in the prior quarter.
• The five-year high for EBITDA was $1.5 million in Q3 2023, with the low at -$24.5 million in Q1 2022.
• Average EBITDA over 5 years is -$11.0 million, with a median of -$10.5 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: EBITDA surged 113.99% in 2023, then plunged 1306.04% in 2024.
• Over 5 years, EBITDA stood at -$10.3 million in 2022, then soared by 107.2% to $741103.1 in 2023, then plunged by 1306.04% to -$8.9 million in 2024, then jumped by 56.69% to -$3.9 million in 2025, then plunged by 217.88% to -$12.3 million in 2026.
• The last three EBITDA figures came in at -$12.3 million (Q2 2026), -$17.7 million (Q1 2026), and -$3.9 million (Q4 2025), per Business Quant data.